: Images of q-FTAA-CN and h-FTAA labelling in human AD brain tissue. A) Staining with 3 µM, q-FTAA-CN fluorescence is observed from Aβ deposits (arrows) and NFTs (arrow heads). B-C) At staining with 100 nM, q-FTAA-CN fluorescence is only observed from Aβ plaques (arrows). D-E) The same section as in B and C after staining with an additional LCO, h-FTAA (1µΜ). The NFTs and dystrophic neurites (arrow heads) are only labeled with h-FTAA (red), whereas both q-FTAA (green) and h-FTAA (red) fluorescence are observed from Aβ deposits (arrows). Scale bar = 20 μm.
Experimental Details

General information
Organic extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo at 40 °C. NMR-spectra were recorded on a Varian instrument 
General procedure for ester hydrolysis (i)
To the dimethyl ester compound in 1,4-dioxane/H2O 2:1 (10 mL/1 mmol) was added NaOH 1 M (1.5 eq/ester). The mixture was stirred until a homogenous solution was obtained and complete hydrolysis was confirmed by LC-MS, after which the solvents were evaporated.
The residual tert-butyl ester compound was dissolved in DCM/TFA 2:1 and the solution was stirred for 2 h or until complete hydrolysis was confirmed by LC-MS, after which the solvents were evaporated.
General procedure for ester hydrolysis (ii)
The tert-butyl ester compound was dissolved in DCM/TFA 2:1 and the solution was stirred for 2 h or until complete hydrolysis was confirmed by LC-MS. The solvents were evaporated.
To the residual methyl ester derivative in 1,4-dioxane/H2O 2:1 (10 mL/1 mmol) was added NaOH 1 M (1.5 eq/ester). The mixture was stirred until a homogenous solution was obtained and complete hydrolysis was confirmed by LC-MS. The solvents were evaporated.
Compound 1
Compound 1 was synthesized as described previously. [1] q-FTAA-NO2
Compound 1 (40 mg, 0.070 mmol) was treated according to the general procedure for ester hydrolysis (i).
To the tricarboxylic acid in DCM (1.5 mL) and TFA (0.5 mL) at 0 °C was added dropwise during one minute a suspension of NaNO2 (10 mg, 0.14 mmol) in TFA (0.25 mL). [2, 3] The reaction mixture was stirred for 30 min at 0 °C and for an additional 2 h at rt. AcOH (concd) and EtOAc were added and the solution was washed with brine and water. The organic phase was dried, filtered and concentrated. Purification by gradient HPLC (C-8, 0-70% eluent A in eluent B in a linear gradient over 15 min followed by isocratic 100% eluent A for 10 min) gave q-FTAA-NO2 (15 mg, 24%) as a red triethylammonium salt. The salt was dissolved in water and 1M NaOH (aq) (0.075 mL, 0.075 mmol). Concentration gave q-FTAA-NO2 as a red sodium salt. 1 
Compound 2
Compound 2 was synthesized as described previously. [1] q-FTAA-Br q-FTAA-Br was synthesized as described previously. [1] q-FTAA-OMe q-FTAA-Br (25 mg, 0.044 mmol), NaOMe (24 mg, 0.44 mmol) and CuBr [4] (6.3 mg, 0,044 mmol) were transferred to a microwave vial and dry MeOH (1.5 mL) and dry DMF (0.5 mL) were added. Microwave irradiation at 125 °C for 60 min followed by filtration of the sample and purification by gradient HPLC (Phenyl-Hexyl, 0-25% eluent C in eluent D in a linear gradient over 25 min followed by isocratic 100% eluent C for 10 min) gave q-FTAA-OMe (4.5 mg, 20%) as an orange solid. The solid was dissolved in water and 1M NaOH (aq) (0.039 mL, 0.039 mmol). 
Compound 3
Compound 3 was synthesized as described previously.
[1]
q-FTAA-I
Compound 3 (31 mg, 0.044 mmol) was treated according to the general procedure for ester hydrolysis (ii). Purification by gradient HPLC (C-8, 0-70% eluent A in eluent B in a linear gradient over 15 min followed by isocratic 100% eluent A for 10 min) gave q-FTAA-I (28 mg, 69%) as an orange triethylammonium salt. The salt was dissolved in water and 1M NaOH (aq) (0.137 mL, 0.137 mmol). Concentration gave q-FTAA-I
as an orange sodium salt. NMR characterization was performed on the triethylammonium salt. 1 
Compound 4
Compound 3 (30 mg, 0.043 mmol), Pd(PPh3)4 (5.0 mg, 0.0043 mmol), Et3N (0.015 mL, 0.11 mmol), DBU (0.021 mL, 0.14 mmol), Mo(CO)6 [5] (12 mg, 0.045 mmol) were transferred to a microwave vial and dry MeOH (0.025 mL) and dry dioxane (0.60 mL)
were added. The vial was flushed with argon and microwave irradiation at 100 °C for give crude compound 4, which was not further characterized prior to hydrolysis (see below).
q-FTAA-CO2H
Crude compound 4 (from previous step) was treated according to the general procedure for ester hydrolysis (ii). Purification by gradient HPLC (C-8, 0-70% eluent A in eluent B in a linear gradient over 15 min followed by isocratic 100% eluent A for 10 min)
gave q-FTAA-CO2H (11 mg, 33% over two steps) as an orange triethylammonium salt. The salt was dissolved in water and 1M NaOH (aq) (0.065 mL, 0.065 mmol).
Concentration gave q-FTAA-CO2H as an orange sodium salt. 
Compound 5
Compound 5 was synthesized as described previously. [1] q-FTAA-CN q-FTAA-CN was synthesized as described previously. [1] q-FTAA-CONH2
Compound 5 (11 mg, 0.018 mmol) was dissolved in DCM:TFA 2:1 (1.5 mL) and the solution was stirred for 2 h and the solvents were evaporated.
To the residue suspended in 1,4-dioxane/H2O 2:1 (1.5 mL) was added NaOH (0.18 mL, 0.18 mmol) and the mixture was heated at 50 °C for 2 h. Purification by gradient HPLC (C-8, 0-70% eluent C in eluent D in a linear gradient over 15 min followed by isocratic 100% eluent C for 10 min) gave q-FTAA-CONH2 (7.5 mg, 78%) as an orange solid.
The salt was dissolved in water and 1M NaOH (aq) (0.063 mL, 0.063 mmol).
Concentration gave q-FTAA-CONH2 as an orange sodium salt. 1 
Preparation of recombinant Aβ(1-42) fibrils
Amyloid fibrils were prepared from recombinant Aβ(1-42) (rPeptide (Bogart, GA)) dried from hexafluoroisopropanol (HFIP) as described previously. [6] Briefly, the peptide (1 mg) was dissolved in distilled H2O for 30 min on ice. NaN3 (0.01 volume) and 10X PBS (0.1 volume) were added to give final concentrations of 20 mM sodium phosphate, 0.145 M NaCl, 0.02% NaN3, pH 7.5. After transfer to 1.8 mL screw-cap polypropylene tubes they were incubated in a water bath at 37 °C for 6 days, vortexing briefly once a day. Fibril formation was confirmed by amyloid-specific fluorescence of
ThT according to published methods. [8] All of the peptide and ThT fluorescence sedimented at 16,000 x g for 15 min. Fibrils were stored in aliquots in polypropylene tubes at -20 °C.
Binding studies with 3 H-X-34 and 3 H-PIB
3 H-X-34 binding was carried out as described previously. [6] 66 ng (14. values determined graphically from log-logit plots (SigmaPlot 12.3). 3 H-PIB binding (1.3 nM, 77 Ci/mmole) was carried out similarly, as described using 1 µM BTA-1 to determine non-specific binding of PIB. [7] Antibody and LCO staining of brain sections with AD-pathology Tissue sections stained by only LCOs were fixed in ethanol (10 min) and rehydrated with water followed by PBS. The sections were stained with q-FTAA-CN (stock solutions: 1.5 mM in de-ionized water; diluted to 100 nM or 3 µM in PBS) for 30 min at RT. Thereafter, the sections were rinsed in PBS, mounted with Dako mounting solution for fluorescence (Dako, Glostrup, Danmark) and examined using a Zeiss confocal microscope, LSM 780 (Carl Zeiss AG, Germany). For the section stained by 100 nM q-FTAA-CN, the cover glass was removed and stained with h-FTAA stock solutions: 1.5 mM in de-ionized water; diluted to 1 µM in PBS) for 30 min. After washing with PBS, the section was analyzed as described above. 0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220  230 f1 ( -10  0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220  230 f1 ( -10  0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220  230 0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220  230 f1 ( 
